Decitabine

目录号:S1200 别名: Deoxycytidine

Decitabine Chemical Structure

Molecular Weight(MW): 228.21

Decitabine是DNA甲基转移酶抑制剂,整合进入DNA、导致DNA低甲基化,并使DNA复制停滞在intra-S-phase。Decitabine被用于治疗骨髓增生异常综合征(MDS)。

规格 价格 库存 购买数量  
RMB 1269.11 现货
RMB 732.42 现货
RMB 1419.77 现货
RMB 2621.82 现货
RMB 4679.47 现货
有超大折扣

今日订购,明日送达,全国免运费!

全国免费电话:400-668-6834   |   Email:info@selleck.cn

客户使用该产品的3个实验数据:

  • (A) and (B) SW1116 and LOVO cells were plated, treated for 48 h with decitabine (DAC) and gefitinib (GEF) either alone or in combination, and the expression levels of AKT, mTOR, S6K, and phosphorylation were determined by Western blot analysis as described under Methods. Expression of β-actin served as a loading control. The data are representative of three independent experiments.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

    (A) and (B) SW1116 and LOVO cells were cultured in control conditions (DMSO) or in the presence of the indicated concentrations of decitabine (DAC) and gefitinib (GEF), alone or in combination, for 48 h. And then cells were stained with Annexin V-FITC and propidium iodide (PI) and analyzed by flow cytometry. This experiment was done in triplicate and representative diagrams of Annexin V-FITC assays are shown.

    PLoS One 2014 9(5), e97719. Decitabine purchased from Selleck.

  • Leuk Res 2014 38(3), 402-10. Decitabine purchased from Selleck.

产品安全说明书

DNA Methyltransferase抑制剂选择性比较

生物活性

产品描述 Decitabine是DNA甲基转移酶抑制剂,整合进入DNA、导致DNA低甲基化,并使DNA复制停滞在intra-S-phase。Decitabine被用于治疗骨髓增生异常综合征(MDS)。
特性 Decitabine 是DNA甲基化的有效抑制剂。
靶点
DNA methylation [1]
(HL-60, KG1a cells)
体外研究

Decitabine 有效抑制DNA 合成,这种作用存在剂量依赖性,作用于HL-60和 KG1a 白血病细胞时,IC50分别为 100 ng/mL 和1 ng/mL。Decitabine 抑制细胞生长,这种作用存在剂量和时间依赖性,处理HL-60和KG1a白血病细胞72小时和96小时,IC50分别约为100 ng/mL 和 10 ng/mL。[1] 最新研究显示Decitabine作用于间变性大细胞淋巴瘤(ALCL),具有抗增殖和促凋亡活性,且抑制KARPAS-299细胞中[3H]胸甘的摄取,EC50 为0.49 μM。[2]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
Eca109 M2O0V2Z2dmO2aX;uJGF{e2G7 MY[wMlXDqM7:TR?= NX\ue4lEOjRiaB?= M3XiOZdifGW{ M1\2bo1w\HWuYYTld{B1cGViZ3Xu[UBmgHC{ZYPzbY9vKG:oIF3BS2UuSSCvZX3i[ZJ{ MnnVNlUyOjNyOEK=
Eca109 NUHOcJl5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU[wMlUwOi53L{Wg{txO NV3rNGNFOjRxNEivO|IhcA>? M3ey[5difGW{ NFy1RmNqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGSxc3WtJIFv\CC2aX3lMUBl\XCnbnTlcpQhdWGwbnXy NW\LO5VjOjVzMkOwPFI>
Eca109 M3\qeGZ2dmO2aX;uJGF{e2G7 MV[wMlXDqM7:TR?= M3;SclYwOTJxMkSgbC=> MUj3ZZRmeg>? NWLtPHhmcW6qaXLpeJMh[2WubDDtbYdz[XSrb39CpC=> NF[xd2MzPTF{M{C4Ni=>
Eca109 MoPaSpVv[3Srb36gRZN{[Xl? NWjIcFhIOC53wrFOwG0> MUiyOEBp NIDocXV4[XSnch?= M2DmO4lvcGmkaYTzJINmdGxiaX72ZZNqd25? MnjBNlUyOjNyOEK=
Eca109 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;OclAvPcLizszN NYTpcIl2OjRiaB?= MnS3e4F1\XJ? MlfvbY5lfWOnczDHNk9OKGG{cnXzeEBqdiC2aHWgZ4VtdCCleXPs[S=> MV:yOVEzOzB6Mh?=
Eca109 NFP0XJlHfW6ldHnvckBCe3OjeR?= NWXBdopWOC53L{Gg{txO NYjFV|c2OjRiaB?= NGjlfnV4[XSnch?= MnGz[IVkemWjc3XzJIV5eHKnc4Ppc44hd2ZiTl[t{tpDOiCjbnSgUW1ROg>? MWeyOVEzOzB6Mh?=
SW1116  NFy5OGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXnZY8xNjVxMT:yM|Uh|ryP NV;MVVlEPDhiaB?= NI\MSWVFVVOR NYDNeHpb\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? NX7Pc|BoOjR6N{SyPFY>
LOVO M4LwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjKNE42NzFxMj:1JO69VQ>? M3;6U|Q5KGh? MWnEUXNQ NVnSWZlt\W6qYX7j[ZMhfGinIFfl[ol1cW6rYjDpcoR2[2WmIHPlcIwhcW6qaXLpeIlwdg>? M2SwZlI1QDd2Mki2
SW1116  NWT1VZpsTnWwY4Tpc44hSXO|YYm= MWexNEDPxE1? MnzEOFghcA>? MnP3SG1UVw>? Ml7LbY5kemWjc3XzJJRp\SCnZn\lZ5RqfmViYYSgbY5pcWKrdHnu[{BCU1RiYX7kJI1VV1Jic3nncoFtcW6pIIDheIh4[Xm|IHPvcYJqdmWmIIfpeIgh\2WoaYTpcolj MVeyOFg4PDJ6Nh?=
LOVO M17jWGZ2dmO2aX;uJGF{e2G7 MVOxNEDPxE1? M37qNFQ5KGh? NGPOcXBFVVOR MWfpcoNz\WG|ZYOgeIhmKGWoZnXjeIl3\SCjdDDpcohq[mm2aX7nJGFMXCCjbnSgcXRQWiC|aXfuZYxqdmdicHH0bJdigXNiY3;tZolv\WRid3n0bEBo\W[rdHnubYI> MWKyOFg4PDJ6Nh?=
SW1116  MWjBdI9xfG:|aYOgRZN{[Xl? M1jFWFExKM7:TR?= MUO0PEBp MX7EUXNQ NGH0dIJmdmijbnPld{BI\W[rdHnubYIucW6mdXPl[EBieG:ydH;zbZM> NEO1XG4zPDh5NEK4Oi=>
LOVO M2T1PGFxd3C2b4Ppd{BCe3OjeR?= NUTBeodGOTBizszN NUDqRVZQPDhiaB?= MXTEUXNQ NVTnZpFu\W6qYX7j[ZMhT2WoaYTpcoljNWmwZIXj[YQh[XCxcITvd4l{ MUKyOFg4PDJ6Nh?=
RPMI-8226 NEXTUGdCeG:ydH;zbZMhSXO|YYm= MlvBNU8zKM7:TR?= M37ufFQ5Nzd{L{m2JIg> MXXEUXNQ MYrpcoR2[2W|IHPlcIwh[XCxcITvd4l{ MkfwNlQ5OzNzMEi=
OPM-2  NWnxVpY4SXCxcITvd4l{KEG|c3H5 M3nFTlEwOiEQvF2= NWrRUm1GPzJxOU[vNVIxKGh? NVL0UlVuTE2VTx?= M1fMVolv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NXLuVYl4OjR6M{OxNFg>
JJN3  NITqbZhCeG:ydH;zbZMhSXO|YYm= MVWwMlUwOSEQvF2= NGPEb5MzPC92ODDo MVXEUXNQ M2OwRYlv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NXr0U4pmOjR6M{OxNFg>
NCI-H929  MV\BdI9xfG:|aYOgRZN{[Xl? NUnhSHp3OS9{IN88US=> M4HROVczNzl4L{GyNEBp MUfEUXNQ M3PlU4lv\HWlZYOgZ4VtdCCjcH;weI9{cXN? NUS3[3ZROjR6M{OxNFg>
RPMI-8226 MkXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV;oWWR{OS9{IN88US=> M2nsR|I1NzR6L{eyJIg> NUW2S5E2TE2VTx?= NF3C[Fli\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NF\WU5EzPDh|M{GwPC=>
OPM-2  Mn3vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NITBN|IyNzJizszN MlXqNlQwPDhxN{KgbC=> NYTUSHRSTE2VTx?= NGPWdnFi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= NXnPW4h4OjR6M{OxNFg>
JJN3  M2jYc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWOwMlUwOSEQvF2= M3\INFI1NzR6L{eyJIg> NYPrdldOTE2VTx?= NEjYblZi\m[nY4TzJINmdGxiY4njcIUheHKxZ4Lld5Nqd25ibnXnZZRqfmWueR?= MkmzNlQ5OzNzMEi=
NCI-H929  NX7jXnpLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrC[VAyNzJizszN Mon4NlQwPDhxN{KgbC=> NY\4WGxJTE2VTx?= NV7icmRJ[W[oZXP0d{Bk\WyuIHP5Z4xmKHC{b3fy[ZN{cW:wIH7l[4F1cX[nbIm= M1PDPVI1QDN|MUC4
HeLa Ml\vT4lv[XOnIFHzd4F6 MXTLbV0yODBy4pETOVAxOCEQvF2g[o9zKGiHTmSx M1nxN|I1PzhyMEm4
HeLa MYPLbY5ie2ViQYPzZZk> NVXnU4tNU2l;NT62JOKyKDBwNTFOwG0h\m:{IHjFUnQz M{\IcVI1PzhyMEm4
HeLa MYrLbY5ie2ViQYPzZZk> MWjLbV0zOS54INMxJFMvOCEQvF2g[o9zKGiFTmSx NFzScY8zPDd6MEC5PC=>
HeLa MYXLbY5ie2ViQYPzZZk> M{fUNmtqRTF2LkSgxtEhPC54IN88UUBnd3JiaFPOWFM> NUPRV4lsOjR5OECwPVg>
NB4 NV3ncWlSTnWwY4Tpc44hSXO|YYm= NXrl[IxKOi53L{WvO{42NzFyIN88US=> MkjiNlQhcA>? NV3j[nlCTE2VTx?= MmLGbY5kemWjc3XhJJRp\SCneIDy[ZN{cW:wIH;mJJBz\WO3coPvdkBucVJvMUK1ZS=> MmPlNlQ1QDR6N{C=
CD4+ CD25− T  NFXabZJHfW6ldHnvckBCe3OjeR?= MkS1NU82KM7:TR?= NWXPSlhJemWmdXPlV{BodG:kYXygSG5CKG2ndHj5cIF1cW:w MYOyOFQ4PjN4MB?=
BV-173 M2HFTWFxd3C2b4Ppd{BCe3OjeR?= MlfRNE4zPS9yLkWvNE44PS9zIN88US=> M2HZbVQ5Nzd{L{m2JIg> NID6XlTDqFCEUx?= NHq2bm5qdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhiZH;z[U0h[W6mIITpcYUuKGSncHXu[IVvfCCvYX7u[ZI> M37ZSVI1PDJ|NkGz
ML-1 MVPBdI9xfG:|aYOgRZN{[Xl? Mo\CNE4zPS9yLkWvNE44PS9zIN88US=> NV\aRnJNPDhxN{KvPVYhcA>? MYdCpHBDWw>? M4XKS4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNiaX6gZo91cCCmb4PlMUBidmRidHnt[U0h\GWyZX7k[Y51KG2jbn7ldi=> NETOdVczPDR{M{[xNy=>
HL-60 M{HXNmFxd3C2b4Ppd{BCe3OjeR?= NWLZZYZnOC5{NT:wMlUwOC55NT:xJO69VQ>? NXvhfYo{PDhxN{KvPVYhcA>? NUT3[FdUyqCSQmO= NVjVVVdFcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz NYPNWJBCOjR2MkO2NVM>
KG-1a Mn3FRZBweHSxc3nzJGF{e2G7 MmDYNE4zPS9yLkWvNE44PS9zIN88US=> NFG3PW81QC95Mj:5OkBp NI[yU|LDqFCEUx?= NUHzRWs{cW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIHTvd4UuKGGwZDD0bY1mNSCmZYDlcoRmdnRibXHucoVz MWCyOFQzOzZzMx?=
BV-173 NV;uZVl7TnWwY4Tpc44hSXO|YYm= MWqyOVAwPTBybl2= NVjXeFhuPDhiaB?= M370ZuKhWEKV MUPpcoR2[2W|IHTlcIF6\WRiYX7kJJN2e3SjaX7l[EBTV1NiaX7jdoVie2V? MVKyOFQzOzZzMx?=
CEM NUPjPY1XTnWwY4Tpc44hSXO|YYm= Mo\sNlUxNzVyMH7N NWn4fIRvPDhiaB?= Ml64xsBRSlN? NE\tVHZqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= MUeyOFQzOzZzMx?=
HL-60 MlTPSpVv[3Srb36gRZN{[Xl? M3X1eVI2OC93MEDuUS=> MU[0PEBp MUJCpHBDWw>? NFTPZ|hqdmS3Y3XzJIRmdGG7ZXSgZY5lKHO3c4ThbY5m\CCUT2OgbY5kemWjc3W= MWGyOFQzOzZzMx?=
ML-1 NY\ke4l{TnWwY4Tpc44hSXO|YYm= NFfEVYMzPTBxNUCwcm0> M32zOFQ5KGh? NFT2W2rDqFCEUx?= NUC3doVNcW6mdXPld{Bl\WyjeXXkJIFv\CC|dYP0ZYlv\WRiUl;TJIlv[3KnYYPl MXeyOFQzOzZzMx?=
DLD-1 NHmwN29HfW6ldHnvckBCe3OjeR?= MWGyOVAwPTBybl2= NUm5RVdyPDhiaB?= MnrFxsBRSlN? NFnMPZpldyCwb4SgbY5lfWOnczDk[YxigWWmIHHu[EB{fXO2YXnu[YQhWk:VIHnuZ5Jm[XOn M{TwdlI1PDJ|NkGz
HCT-116 M4LJXWZ2dmO2aX;uJGF{e2G7 NHHrOlIzPTBxNUCwcm0> MkG3OFghcA>? NYS1R|NxyqCSQmO= NV3XeGVw\G9ibn;0JIlv\HWlZYOg[IVt[XmnZDDhcoQhe3W|dHHpcoVlKFKRUzDpcoNz\WG|ZR?= NYfpbok2OjR2MkO2NVM>
U937-A/E-9/14/18  Ml\ZRZBweHSxc3nzJGF{e2G7 MWKwMlAyNzBwMT:xM|ExKM7:TR?= NYPDNmZvPDhiaB?= MoH6bY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Ml7xNlQ{ODB2NU[=
HT29 NYCxRXZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7oe5k4OiCq NIjpRY1KSzVyPUG0NFDDuTF5OTFOwG0> MVKyOFE4OjB4MR?=
SW48 NVTtfmVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVT4PXEzPzJiaB?= MUPJR|UxRTF3LkNCtVYvOiEQvF2= NIr6NlEzPDF5MkC2NS=>
HCT116 NFKyXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4fBS|czKGh? NEjGUoZKSzVyPUGuO:KyOC52IN88US=> NX:1RZVFOjRzN{KwOlE>
HepG2 NU\JcIZITnWwY4Tpc44hSXO|YYm= MlHuNE42NzFizszN MUSyOEBp NGHXeY9FVVOR M3m2O5VxNXKnZ4XsZZRm\CC2aHWgdoVt[XSrdnWgU2NVVjJibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w M1m2WFI1OTR4OEe0
LS174T Ml2wSpVv[3Srb36gRZN{[Xl? MWiwMlUwOSEQvF2= NVS4d2p2OjRiaB?= NFrsTpVFVVOR NUT0VY5mdGWjZDD0c{BidiCrbnPy[YF{\SCxZjDPR3RPOiCuZY\lcJM> NETVXmozPDF2Nki3OC=>
HepG2 NEPmVlRCeG:ydH;zbZMhSXO|YYm= NIT5So8yNzFyL{GwNEDPxE1? MVK3JIQ> NUnnSZZsTE2VTx?= MUDpcoR2[2W|IHPlcIwh[XCxcITvd4l{KGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz NXHrclRPOjRzNE[4O|Q>
LS174T NVHlN5E5SXCxcITvd4l{KEG|c3H5 NWjKW25[OS9zMD:xNFAh|ryP MkPnO{Bl NGfCeJZFVVOR NV;QWYljcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= Mlu0NlQyPDZ6N{S=
QBC-939 NHjUUohCeG:ydH;zbZMhSXO|YYm= Mm\GNU8yOC9zMECg{txO MVi3JIQ> NWXIfWRyTE2VTx?= Ml;DbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MWqyOFE1Pjh5NB?=
U251 NWD2[pN7SXCxcITvd4l{KEG|c3H5 MVGxM|ExNzFyMDFOwG0> NXWyelRiPyCm MmTLSG1UVw>? NEGzNlRqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ MoD6NlQyPDZ6N{S=
HL-60 NHvUWmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVG1TmVEOSEQvF2= M1yxWFQ5KGh? M3[yPYlv[3KnYYPld{BIOi2yaHHz[UBk\WyuIH\yZYN1cW:w M160TFI1ODByM{K0
MDA‑MB‑453 NF;rVG5HfW6ldHnvckBCe3OjeR?= Mlu3NE4zNzFizszN NV3OXGY2PzJiaB?= MlXqZ4F2e2W|IILlMYV5eHKnc4Ppc44hd2ZiY3zheYRqdsLiMdMg NYLGOmVGOjN6NESyNlg>
HCC1569 Mk\JSpVv[3Srb36gRZN{[Xl? M2G4WFAvOi9zIN88US=> MWW3NkBp M4\TUYNifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> NV72boRQOjN6NESyNlg>
BT‑474 M1H1TWZ2dmO2aX;uJGF{e2G7 MkT2NE4zNzFizszN M1TscFczKGh? M2LKUINifXOnczDy[U1mgHC{ZYPzbY9vKG:oIHPsZZVlcW8EoEJCpC=> NEf4[3czOzh2NEKyPC=>
AGS MUXBdI9xfG:|aYOgRZN{[Xl? NULTd4ZTPS9zMD:yNE82OCEQvF2= NUXS[JRbPDkEoHlCpC=> M3XEVGROW09? NGS0XoJqdmirYnn0d{B1cGViY3XscEB3cWGkaXzpeJnDqA>? MnfDNlM2QDJ5OES=
A549 MYLBdI9xfG:|aYOgRZN{[Xl? MYS1M|ExNzJyL{WwJO69VQ>? MV60POKhcMLi NGr3RlZFVVOR MmDhbY5pcWKrdIOgeIhmKGOnbHygeoli[mmuaYT5xsA> NEP5bGwzOzV6Mke4OC=>
AGS  MkjNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlriOU8yOC9{MD:1NEDPxE1? NGXSTZc1QMLiaNMg NUK5[HEzTE2VTx?= NHPaVm1qdmS3Y3XzJGczN01icHjhd4Uh[XK{ZYP0xsA> NHK2OGczOzV6Mke4OC=>
Kasumi-1 MWHBdI9xfG:|aYOgRZN{[Xl? M3zxb|AvPSEQvF2= MoHiOFjDqGkEoB?= MYTk[YNz\WG|ZYOgeIhmKGOnbHygeoli[mmuaYT5JINwNXS{ZXH0[YQhf2m2aDDU[k1PWC2|Yx?= MmPXNlM1QTN|NEi=
OCI-AML3 NYnOTWxzSXCxcITvd4l{KEG|c3H5 NF:xbIQzNjVizszN M4rPSVQ5yqCqwrC= NGnZRVJl\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> M4\hW|I{PDl|M{S4
MV4-11 NY\nVYh[SXCxcITvd4l{KEG|c3H5 M4nzSVIvPSEQvF2= NELnNlY1QMLiaNMg NGTQbW1l\WO{ZXHz[ZMhfGinIHPlcIwhfmmjYnnsbZR6KGOxLYTy[YF1\WRid3n0bEBV\i2QUD3zZy=> MXSyN|Q6OzN2OB?=
NK  NFPZ[YZEgXSxdH;4bZR6KEG|c3H5 NV7XOoZVOC5yMj2yNEDPxE1? NEfjUGQ2KGR? NHXkW3Rl\WO{ZXHz[ZMhfGinIHP5eI9tgXSrYzDhZ5Rqfmm2eTDv[kBPUyClZXzsd{BifCCrboTldo1m\GmjdHWgZ49v[2WwdILheIlwdnNicnXzeYx1cW6pIHnuJIEhXS2|aHHw[YQh\G:|ZfMAl5Jme3CxboPlJIN2en[n MofFNlM{OjhyOEi=
NK  NWfQOmVKSXCxcITvd4l{KEG|c3H5 Mm\5NE4xOi1{MDFOwG0> NGXreII2KGR? M{LpZoRm[3KnYYPlJG5MKGOnbHygdJJwdGmoZYLheIlwdiCjbnSgeoli[mmuaYT5JIF{KHSqZTDjc45k\W62cnH0bY9vKGmwY4LlZZNm\A>? NFXLcVYzOzN{OEC4PC=>
NK  MX\GeY5kfGmxbjDBd5NigQ>? NUO4SHo1OC5yMT2yNEDPxE1? NXvOVG06PSCm MmnPZ4F2e2W|IHj5dI9u\XSqeXzheIlwdiCxZjDOT{Bk\WyuczDpckBiKGSxc3ZihLNz\XOyb37z[S=> M2DPWlI{OzJ6MEi4
MOLT4/DNR MmHmSpVv[3Srb36gRZN{[Xl? MnTKOUDPxE1? M4LRbVQh\A>? M4T6XZJm\HWlZYOgRWJESjFibWLORUBmgHC{ZYPzbY9v MojONlMxPjB3N{C=
Jurkat/DOX M3zIcmZ2dmO2aX;uJGF{e2G7 NIrXfmg2KM7:TR?= NEPoc5Q1KGR? MWny[YR2[2W|IFHCR2IyKG2UTlGg[ZhxemW|c3nvci=> NIm0fWgzOzB4MEW3NC=>
MOLT4/DNR NXHEdY5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLuV|BKPSEQvF2= MXq0JIQ> MknFdoVlfWOnczD0bIUhUUN3MNMgeoFtfWViZn;yJIRifW6xcoXibYNqdiC|ZX7zbZRqfmm2eR?= M4ixNlI{ODZyNUew
Jurkat/DOX Mm\0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4TRS|Uh|ryP M2TqXVQh\A>? MV;y[YR2[2W|IITo[UBKSzVywrD2ZYx2\SCob4Kg[IF2dm:{dXLpZ4lvKHOnboPpeIl3cXS7 MXuyN|A3ODV5MB?=
ccRCC  NVnERXE6SXCxcITvd4l{KEG|c3H5 NInBU5IxNjBzLUGw{txO NHmwNXU4OiCq NHLZTYZFVVOR MUHoZZMhdWmwaX3hcEBm\m[nY4Sgc44h[2WubDDwdo9tcW[ncnH0bY9v MnjDNlI5OjZ2Nke=
TNBC  Moj3RZBweHSxc3nzJGF{e2G7 M3i0UlAvODFvMUFOwG0> NWTuPYpNPzJiaB?= NX3J[2tLTE2VTx?= NUn0UWJ{cGG|IH3pcolu[WxiZX\m[YN1KG:wIHPlcIwheHKxbHnm[ZJifGmxbh?= MVmyNlgzPjR4Nx?=
A498 NF:wZ|dCeG:ydH;zbZMhSXO|YYm= NIXPTpIxNjBzLUGw{txO NU\HWWV7PzJiaB?= NHv1dI9FVVOR Ml7EbY5lfWOnczDzfY5memerc4TpZ{Bz\XOyb37z[ZPDqHerdHigdo9ucWSncIPpci=> M1rlZVIzQDJ4NE[3
KIJ265T MYPBdI9xfG:|aYOgRZN{[Xl? M2HwSFAvODFvMUFOwG0> MkiwO|IhcA>? NGGwS3dFVVOR MVfpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MYOyNlgzPjR4Nx?=
MDA-231 Mkj1RZBweHSxc3nzJGF{e2G7 MkHxNE4xOS1zMN88US=> NY\hbpF5PzJiaB?= NFK3dnZFVVOR MYHpcoR2[2W|IIP5coVz\2m|dHnjJJJme3CxboPld:Khf2m2aDDyc41q\GWyc3nu MmTLNlI5OjZ2Nke=
BT-20 M{PwNmFxd3C2b4Ppd{BCe3OjeR?= MUGwMlAyNTFyzszN MYe3NkBp NXTPbpBsTE2VTx?= NH3h[llqdmS3Y3XzJJN6dmW{Z3nzeIlkKHKnc4DvcpNme8Lid3n0bEBzd22rZHXwd4lv Mof5NlI5OjZ2Nke=
U937 M1\Lcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWO1MVIxKM7:TR?= M1nSSVI1NzR6L{eyJIg> NITrPXhqdmS3Y3XzJIEh\GWlcnXhd4UhcW5iY3XscEB3cWGkaXzpeJkhcW5iYTDjc45k\W62cnH0bY9vNSCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz MYqyNlc3PzB{MR?=
HL60 NUW3V2tKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWC1MVIxKM7:TR?= MlXCNlQwPDhxN{KgbC=> MmXDbY5lfWOnczDhJIRm[3KnYYPlJIlvKGOnbHygeoli[mmuaYT5JIlvKGFiY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NYjOW4JkOjJ5NkewNlE>
U937 NHfTbmxCeG:ydH;zbZMhSXO|YYm= NXTzeFU6OTVizszN NXPMOZhNOjRxNEivO|IhcA>? NGCzVG1qdmS3Y3XzJINmdGxiYYDvdJRwe2m| M4jDRlIzPzZ5MEKx
HL60 NHHJXVFCeG:ydH;zbZMhSXO|YYm= NGe5WFIyPSEQvF2= NXfabpRVOjRxNEivO|IhcA>? Mn21bY5lfWOnczDj[YxtKGGyb4D0c5Nqew>? NVi5cJNROjJ5NkewNlE>
LS411N  MXjBdI9xfG:|aYOgRZN{[Xl? MoHUNE42KM7:TR?= NFG4T5U4OiCq NUTSbnBOcW6lcnXhd4V{KE[jczDtVm5CKGyndnXs M{\5fFIzPDZzNkm1
MDA-MB-231 M33jWWFxd3C2b4Ppd{BCe3OjeR?= NWTR[|BjOTBizszN M3TPO|Q5KGh? NGXZPXNz\WS3Y3XzJINmdGxidnnhZoltcXS7IHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NHLFWFMzOTh6N{[5Oy=>
MCF-7  M2jUOWFxd3C2b4Ppd{BCe3OjeR?= M2XORlExKM7:TR?= NUXT[IdiPDhiaB?= NVfETFhbemWmdXPld{Bk\WyuII\pZYJqdGm2eTDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= NFXq[G4zOTh6N{[5Oy=>
A375 M1W3WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYiwMlUh|ryP NEXISogyNzVxODDk M1rEbIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| NGjHVlYzOTd7Nk[yNi=>
SKMEL1 NHn2OXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnDN4M4OC53IN88US=> NIHrTI0yNzVxODDk NF75enRqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHHu[EBqdmS3Y3XzJIRq\m[ncnXueIlifGmxbjDv[kBu\Wyjbn;tZUBk\Wyucx?= MoKwNlE4QTZ4MkK=
SKMEL3 NULjUZl[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTkNE42KM7:TR?= NEGwXXQyNzVxODDk MVHpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? MUGyNVc6PjZ{Mh?=
SKMEL28 NVezN5BiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX[wMlUh|ryP M{fLbFEwPS96IHS= M3\6eIlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| M4fBZVIyPzl4NkKy
MeWo MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlT3NE42KM7:TR?= NF[0OYQyNzVxODDk M12zOYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iYX7kJIlv\HWlZYOg[Iln\mW{ZX70bYF1cW:wIH;mJI1mdGGwb33hJINmdGy| Moi4NlE4QTZ4MkK=
B16 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fKN|AvPSEQvF2= MkLiNU82NzhiZB?= MULpcohq[mm2czDwdo9tcW[ncnH0bY9vKGGwZDDpcoR2[2W|IHTp[oZmemWwdHnheIlwdiCxZjDt[Yxidm:vYTDj[Yxtew>? NELi[GkzOTd7Nk[yNi=>
Ly 1 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlzBNlQhcA>? NHztToRKSzVyPUeuN{DPxE1? NFrEbYszOTd5MkC0PS=>
Ly 7 NHHUZohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX3nOId2OjRiaB?= MYXJR|UxRTFyLkeg{txO NFXuWlMzOTd5MkC0PS=>
Su-DHL6 NVHzZohtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1n4clI1KGh? MlXqTWM2OO,:nkKwJO69VQ>? NFLnfYUzOTd5MkC0PS=>
Ly 10 NV;Oe|VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\tfmZ6OjRiaB?= MYTJR|Ux97zgMkCg{txO NVzNO3ZCOjF5N{KwOFk>
RIVA NYWyU|QyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoH1NlQhcA>? Mnz2TWM2OO,:nkKwJO69VQ>? NULGPGlIOjF5N{KwOFk>
Su-DHL2 MkjmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnrwNlQhcA>? MoqzTWM2OO,:nkKwJO69VQ>? NHLoRXMzOTd5MkC0PS=>
Ly 1 M4WxbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHq1[mU1QCCq NH3vVJBKSzVyPUCuN|Qh|ryP NXnhWItQOjF5N{KwOFk>
Ly 7 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIS1dI81QCCq NG\5XnlKSzVyPUCuNFI2KM7:TR?= NIXad4gzOTd5MkC0PS=>
Su-DHL6 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3f1c|Q5KGh? MYTJR|Ux97zgMkCg{txO MUmyNVc4OjB2OR?=
Ly 10 M{nXRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYG0PEBp NEnyXnNKSzVyPUGuPEDPxE1? MWOyNVc4OjB2OR?=
RIVA M2LZWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3jvS|Q5KGh? NISyZ5VKSzVy78{eNlAh|ryP NG\6dnczOTd5MkC0PS=>
Su-DHL2 NXjQUodHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nENlQ5KGh? MXrJR|UxRTF5LkSg{txO NUm0fXpDOjF5N{KwOFk>
Ly 1 MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2DrSVczKGh? M4flVWlEPTB;MD6wNUDPxE1? MlP5NlE4PzJyNEm=
Ly 7 NIDBbGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2m4c|czKGh? MmnLTWM2OD1yLkCxPEDPxE1? NGfJTWUzOTd5MkC0PS=>
Su-DHL6 NH3rRmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzLe45XPzJiaB?= NHL0c2FKSzVyPUGuOkDPxE1? NEHxOIwzOTd5MkC0PS=>
Ly 10 Mn;tS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2O5cFczKGh? NHW0WGNKSzVyPUGuNkDPxE1? M4LYcFIyPzd{MES5
RIVA NVX3WJFMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LKN|czKGh? NWf5OVlxUUN3MP-8olIxKM7:TR?= MY[yNVc4OjB2OR?=
Su-DHL2 NI\QOpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE[xTXg4OiCq M2\KUWlEPTB;MUGuNkDPxE1? NX3IcGh1OjF5N{KwOFk>

... Click to View More Cell Line Experimental Data

体内研究 Decitabine 按2.5 mg/kg 剂量作用于ALK+ KARPAS-299小鼠移植瘤模型,促进凋亡,且降低肿瘤细胞增殖,也导致肿瘤抑制基因p16INK4A的去甲基化。 [2]

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

激酶实验:[1]
+ 展开

DNA合成检测 :

通过测定放射性胸甘摄入到DNA的情况而测定DNA合成比率。HL-60 和KG1a 细胞悬浮在6孔(直径为35 mm )盘中,孔中为含10%胎牛血清的2 mL RPMI 培养基中,然后与不同浓度相应药物温育48小时 (药物同时加入)。48小时时, 每孔加入0.5 μCi [3H] 胸甘(6.7 Ci/mmol),再温育24小时。细胞置于GF/C玻璃纤维过滤器(直径为2.4 cm)中,使用冷 0.9% NaCl, 5% 冷三氯乙酸和乙醇清洗。烘干含DNA的过滤器,置于EcoLite闪烁液(ICN)中,使用 Beckman LS 6000IC 闪烁计数器测量放射性。通过剂量-反应曲线计算IC50值。
细胞实验:[1]
+ 展开
  • Cell lines: HL-60 和 KG1a
  • Concentrations: 0 到100 ng/mL
  • Incubation Time: 96 小时
  • Method: 生长抑制实验中,指数生长期细胞接种在5 ml培养基中。向培养基中同时加入不同浓度Decitabine。在指定时间,使用模型 ZM Coulter 计数器对细胞进行计数。根据药物处理的白血病细胞的生长曲线,测定IC50值。
    (Only for Reference)
动物实验:[2]
+ 展开
  • Animal Models: KARPAS-299 人类细胞皮下接种到小鼠的左右两侧。
  • Formulation: Decitabine 溶于无菌PBS
  • Dosages: ≤2.5 mg/kg
  • Administration: 腹腔注射
    (Only for Reference)

溶解度 (25°C)

体外 DMSO 45 mg/mL (197.18 mM)
Water 10 mg/mL (43.81 mM)
Ethanol Insoluble
体内 从左到右依次将纯溶剂加入产品,现配现用(数据来自Selleck实验检测而非文献):
water
10mg/mL

* 溶解度检测是由Selleck技术部门检测的,可能会和文献中提供的溶解度有所差异,这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据

分子量 228.21
化学式

C8H12N4O4

CAS号 2353-33-5
稳定性 powder
in solvent
别名 Deoxycytidine

计算器

摩尔浓度计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系,公式为:

质量 (g) = 浓度 (mol/L) x 体积 (L) x 分子量 (g/mol)

摩尔浓度计算公式

  • 质量
    浓度
    体积
    分子量

*在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。

稀释计算器

稀释计算器

用本工具协助配置特定浓度的溶液,使用的计算公式为:

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入 输出 )

  • C1
    V1
    C2
    V2

在配置溶液时,请务必参考Selleck产品标签上、MSDS / COA(可在Selleck的产品页面获得)批次特异的分子量使用本工具。.

连续稀释计算器方程

  • 连续稀释

  • 计算结果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量计算器

分子量计算器

通过输入化合物的化学式来计算其分子量:

总分子量:g/mol

注:化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量 浓度 体积 分子量
计算

临床试验信息

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03017131 Recruiting Recurrent Fallopian Tube Carcinoma|Recurrent Ovarian Carcinoma|Recurrent Primary Peritoneal Carcinoma Roswell Park Cancer Institute|National Cancer Institute (NCI) December 8 2017 Phase 1
NCT03021395 Recruiting AML Institute of Hematology & Blood Diseases Hospital February 8 2017 Phase 1|Phase 2
NCT03226418 Recruiting Adult Acute Myeloid Leukemia|Secondary Acute Myeloid Leukemia|Therapy-Related Acute Myeloid Leukemia University of Nebraska|National Cancer Institute (NCI) July 7 2017 Phase 2
NCT03356080 Recruiting Acute Myeloid Leukemia|Myelodysplastic Syndrome Shanghai Tong Ren Hospital July 7 2017 Phase 2
NCT02839694 Withdrawn Neoplasm Metastasis|Sarcoma|Neoplasms Germ Cell and Embryonal|Melanoma National Cancer Institute (NCI)|National Institutes of Health Clinical Center (CC) July 7 2016 Phase 1
NCT02203773 Active not recruiting Acute Myelogenous Leukemia|Myelogenous Leukemia|Treatment Naive AML AbbVie|Genentech Inc. July 7 2015 Phase 1|Phase 2

技术支持

在订购、运输、储存和使用我们的产品的任何阶段,您遇到的任何问题,均可以通过拨打我们的热线电话400-668-6834,或者技术支持邮箱tech@selleck.cn,直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题,请给我们留言。

  • * 必填项

常见问题及建议解决方法

  • 问题 1:

    Is S1200 a racemic mixture or a monomer?

  • 回答:

    S1200 is R form

DNA Methyltransferase Signaling Pathway Map

Tags: 购买Decitabine | Decitabine供应商 | 采购Decitabine | Decitabine价格 | Decitabine生产 | 订购Decitabine | Decitabine代理商
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID